Target-based drug development is one of the most important routes to new drug discovery. Ace Therapeutics has built a complete technology service platform for target-based drug development in stroke, including a small molecule library, drug screening platform, drug efficacy testing platform, pharmacokinetic testing platform, safety evaluation testing platform, and pharmaceutic preparation platform. In addition, we provide different services for both nucleic acid targets and protein targets in order to provide more targeted and directional services. Our professional and high-quality services are designed to facilitate the smooth progress of your research.
In stroke pathology, cell activity is crucial for the pathological process, especially in brain cells. Treatment of stroke with neuroprotection focuses on the rescue of neurons in the penumbra. Therefore, the development of stroke drugs against targets of cell activity-regulated processes is a potential way for stroke treatment. Ace Therapeutics provides comprehensive services for cell activity and related assays.
Inflammatory and oxidative stress responses play an important role in stroke pathology. Therefore, the development of stroke drugs for differential targets of inflammatory responses and oxidative stress responses in stroke pathology is a potential therapeutic way. Ace Therapeutics offers comprehensive services to develop new stroke drugs for differential targets of inflammatory responses and oxidative stress responses.
At the same time, inflammatory responses and oxidative stress responses appear in many diseases, which makes targeted stroke drug development more difficult. We aim to solve the challenge with you through our professional and high-quality services.
We offer comprehensive drug development services for other aspects of stroke pathogenesis. At the same time, we can tailor our research services exclusively to your research needs. If you would like to learn more about our services, please feel free to contact us.
We are committed to accelerating progress in stroke research and drug development.